Estimates Revisions Keros Therapeutics, Inc.
Stocks
KROS
US4923271013
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.06 USD | -0.79% |
|
-5.45% | -50.59% |
| 07-22 | Keros Therapeutics, Inc. Announces CFO Changes | CI |
| 07-22 | Keros Therapeutics, Inc. Announces Appointment of Annita Tanini as Interim Principal Accounting Officer, Effective August 4, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
- Stock Market
- Stocks
- KROS Stock
- Consensus Keros Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
